RFP Number : N02CM81010-48
Amendment 1

OFFICE OF ACQUISITIONS NATIONAL CANCER INSTITUTE

REQUEST FOR PROPOSAL NUMBER: N02CM81010-48

Amendment No.: 1

Date of Issuance: 03/10/2008

The above numbered Request For Proposal (RFP) is amended as set forth below. The hour and date specified for receipt of Offerors remains unchanged: by 3:30PM (Local Time) on April 4, 2008.

Offerors MUST acknowledge receipt of the amendment prior to the hour and the date specified in the solicitation or as amended, by separate letter, telegram, or Electronic Mail which includes a reference to the RFP and Amendment number(s). For your convenience, the Proposal Intent Response Form is provided in SECTION J - List of Attachments of this RFP, for this purpose.

FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERORS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.

This Amendment revises the RFP as stated below:

- 1. SECTION A SOLICITATION/CONTRACT FORM is revised to clarify that all questions related to this soliciation should be submitted electronically (via email) to the Contracting Officer, and revised to read as follows: "Please Note: All questions related to this solicitation are due by 3:30PM (Local Time) on March 12, 2008, and should be submitted electronically (via email) to John R. Manouelian, Contracting Officer, at the following email address: manoueli@mail.nih.gov
- 2. SECTION J LIST OF ATTACHMENTS, Attachment 4: Contractor Assessment Report/Performance Indicators and Standards, is revised to correct an incorrect title heading used for Option # 3 and found on both page 4 and page 18 of the attachment.

The original title heading for Option # 3 (on page 4 and 18) read as follows:

"OPTION 3 - Support communications with NCI and stakeholders regarding all aspects of the Initiative."

This amendment revises the title heading for Option # 3 to read as follows:

"OPTION 3 - Manage and support an additional adult CIRB, if required, as a result of expanding the pool of trials reviewed by the CIRB."